. Author manuscript; available in PMC: 2017 Jun 1.

Published in final edited form as: Pediatr Infect Dis J. 2016 Jun;35(6):e164–e170. doi: 10.1097/INF.0000000000001117

Table 5.

Literature review: cancer incidence in HIV-positive children in low, middle and high income countries

Study	Country	Children included	Cancer cases identified	Cancer incidence rate per 100,000 pys (95% CI)		% reduction
				before ART era	during ART era
British Paediatric Association Surveillance Unit³¹	UK	307	11 (7 NHL)	1989-1995 NHL: 1,420	NA	NA
AIDS Cancer Match Study²	USA	4,954	124^* (36 incident in post AIDS period 4 – 27	1980-1995: 656	NA	NA
AIDS Cancer Match Study⁴	USA	5,850	106^*	1980-1995: 550	1996-2007: 213	61%
Pediatric AIDS Clinical Trials Group PACTG³	USA	2,969	37 (17 prevalent, 20 incident)^**	1993-1997: 201 (0–414)	1998-2003: 139 (74–238)	31%
Italian Register HIV Infection in Children²³	Italy	1,331	36	1985-1999: 418 (292–302)		NA
Italian Register HIV Infection in Children⁹	Italy	1,190	35	1985-1995: 449 (237–664)	1996-1999: 409 (168–650) 2000-2004: 76 (0–180)	83%
Uganda Cancer Match Study¹²	Uganda	407	7, prevalent^* 5, incident 2 (KS)	1989-2002: 160		NA
IeDEA-SA	South Africa	11,707	Total 71, prevalent 47, incident 24^**	2000-2004: 111 (60–206)	2005-2011: 69 (41–11)	38%

ADC AIDS-defining cancer; NADC non AIDS-defining cancer; KS Kaposi Sarcoma; NHL non Hodgkin Lymphoma; IeDEA-SA International Epidemiological Databases to Evaluate AIDS in Southern Africa; pys person years; NA not available.

prevalent defined as: before or up to 3 months after AIDS, incident: later than 3 months after AIDS

^**

prevalent defined as: before cohort enrolment, incident: after cohort enrolment